Sugi Predict

Sugi Predict / Compounds / SCHEMBL23901402

SCHEMBL23901402

SCHEMBL23901402

Cc1c(Cl)cc(F)cc1-n1nnc2ccccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNMA1 Q12791 1/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ TSHR P16473 2/20 0.44
▸ GRM2 Q14416 1/20 0.43
▸ ESR1 P03372 1/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ SLC9A1 P19634 2/20 0.39
▸ KEAP1 Q14145 1/20 0.39
▸ KMT2A Q03164 4/20 0.39
▸ ALDH1A1 P00352 3/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ RECQL P46063 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ POLB P06746 1/20 0.38
▸ GAA P10253 2/20 0.38
▸ MGAM O43451 1/20 0.37
▸ AMY1A P0DUB6 1/20 0.37
▸ SI P14410 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8844809 0.80 KCNMA1 (0.55) KCNMA1SMN1; SMN2TSHRRAB9ASLC9A1
SCHEMBL14536274 0.78 SMN1; SMN2 (0.49) KCNMA1SMN1; SMN2TSHRRAB9ASLC9A1
SCHEMBL25729094 0.74 SMN1; SMN2 (0.49) KCNMA1SMN1; SMN2TSHRRAB9ASLC9A1
SCHEMBL25862494 0.74 KCNMA1 (0.64) KCNMA1SMN1; SMN2TSHRESR1RAB9A
SCHEMBL25021088 0.74 KCNMA1 (0.55) KCNMA1SMN1; SMN2TSHRESR1RAB9A
SCHEMBL16728738 0.72 SMN1; SMN2 (0.43) KCNMA1SMN1; SMN2TSHRGRM2ESR1
SCHEMBL25873809 0.72 KCNMA1 (0.50) KCNMA1SMN1; SMN2TSHRESR1RAB9A
SCHEMBL25873798 0.72 KCNMA1 (0.50) KCNMA1SMN1; SMN2TSHRESR1RAB9A
SCHEMBL24248002 0.72 SMN1; SMN2 (0.47) KCNMA1SMN1; SMN2TSHRESR1RAB9A
SCHEMBL24022194 0.72 SMN1; SMN2 (0.50) KCNMA1SMN1; SMN2TSHRRAB9ASLC9A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718588-B2 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis GALAPAGOS NV (BE) 2023-08-08 — — US disclosed
US-11718588-B2 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis GALAPAGOS NV (BE) 2023-08-08 — — US disclosed
US-20210309614-A1 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS GALAPAGOS NV (BE) 2021-10-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210309614-A1 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS ADAMTS1, ADAMTS5, ADAMTS7 KCNMA1 2195/4885SMN1; SMN2 3600/4885TSHR 3353/4885
US-11718588-B2 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis ADAMTS1, ADAMTS5, ADAMTS7 KCNMA1 2195/4885SMN1; SMN2 3600/4885TSHR 3353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.